Incomplete ileus and hemafecia as the presenting features of multi-organ involved primary systemic AL amyloidosis: a rare case report
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Diseases. 2016;2(1):17–22.
Basavaraju KP, Mansour D, Barnes S, Whitehead MW, Bruce SA. A rare cause of dysphagia and gastroparesis. BMJ Case Rep. 2009; doi: 10.1136/bcr.07.2008.0358 .
Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol. 2002;22(4):319–30.
Cichoz-Lach H, Prozorow-Krol B, Swatek J, Buk L, et al. Hepatomegaly, weight loss and general malaise - the first manifestations of primary systemic amyloidosis. Prz Gastroenterol. 2014;9(1):57–61.
Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98(1):141–6.
Tada S, Lida M, Iwashita A, Matsui T, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc. 1990;36(1):10–4.
Sattianayagam P, Gibbs S, Hawkins P, Gillmore J. Systemic AL (light chain) amyloidosis and the gastrointestinal tract. Scand J Gastroenterol. 2009;44:1384–5.
James DG, Zuckerman GR, Sayuk GS, Wang HL, Prakash C. Clinical recognition of al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol. 2007;5(5):582–8.
Kumar S, Senqupta RS, Kakkar N, Sharma A, et al. Skin involvement in primary systemic amyloidosis. Mediterr J Hematol Infect Dis. 2013;5(1):e2013005.
Bely M, Apathy A. Histochemical and immunohistochemical differential diagnosis of amyloidosis--a brief illustrated essay and personal experience with Romhanyi's method. Amyloid. 2000;7(3):212–7.
Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc. 1999;74(5):490–4.
Uversky VN. Nanoimaging in protein-misfolding and onformational diseases. Nanomedicine (Lond). 2007;2:615–43.
Silva L, Sampaio L, Terroso G, Almeida G, Lucas R, Rios E, et al. Amyloidosis secondary to rheumatic diseases: 16 cases. Acta Reumatol Port. 2010;35:518–23.
Wright JR, Calkins E, Humphrey RL. Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of the disease. Lab Investig. 1977;36:274–81.
Palladini G, Russo P, Nuvolone M, Lavatelli F, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787–8.
Palladini G, Perfetti V, Obici L, Caccialanza R, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936–8.
Obici L, Perfetti V, Palladini G, Moratti R, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11–22.
Palladini G, Campana C, Klersy C, Balduini A, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.